Cargando…

A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy

Background: To investigate whether the radiomics signature (Rad-score) of DCE-MRI images obtained in triple-negative breast cancer (TNBC) patients before neoadjuvant chemotherapy (NAC) is associated with disease-free survival (DFS). Develop and validate an intuitive nomogram based on radiomics signa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Bingqing, Wang, He, Wang, Zhe, Qian, Zhaoxia, Xiao, Qin, Liu, Yin, Shao, Zhimin, Zhou, Shuling, Chai, Weimin, You, Chao, Gu, Yajia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632946/ https://www.ncbi.nlm.nih.gov/pubmed/34868273 http://dx.doi.org/10.3389/fgene.2021.783513

Ejemplares similares

A Nomogram to Predict Disease-Free Survival Following Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
por: Zhu, Meizhen, et al.
Publicado: (2021)

Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy
por: Li, JunJie, et al.
Publicado: (2016)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016)

Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy
por: Zhang, Wei, et al.
Publicado: (2023)

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
por: Castrellon, Aurelio Bartolome, et al.
Publicado: (2017)

Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
por: Ghallab, Ahmed
Publicado: (2020)

Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
por: Ding, Feng, et al.
Publicado: (2022)

The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Johnson, Kai Conrad Cecil, et al.
Publicado: (2023)

Platinum is essential in neoadjuvant treatment of triple-negative breast cancer: a network meta-analysis
por: Li, Junjie, et al.
Publicado: (2022)

Nomogram for Predicting Breast Conservation after Neoadjuvant Chemotherapy
por: Kim, Min Kyoon, et al.
Publicado: (2015)

Immune Cell Infiltration-Based Characterization of Triple-Negative Breast Cancer Predicts Prognosis and Chemotherapy Response Markers
por: Lv, Yufei, et al.
Publicado: (2021)

Immunotherapy in combination with neoadjuvant anthracycline‑free chemotherapy for triple‑negative early breast cancer: A case report
por: Zhao, Xiangwang, et al.
Publicado: (2023)

Male Triple-Negative Breast Cancer
por: Qavi, Qasif, et al.
Publicado: (2021)

Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients
por: Wang, Ruo-Xi, et al.
Publicado: (2018)

Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
por: Li, Zhijun, et al.
Publicado: (2023)

NMR-Based Metabolomics Analysis Predicts Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: He, Xiangming, et al.
Publicado: (2021)

Clinical Observation of Zhengyuan Capsule Combined with Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Zhang, Xiaoyu, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy Combined with Breast-Conserving Surgery in the Treatment of Triple-Negative Breast Cancer
por: Zhang, Xiaoyu, et al.
Publicado: (2022)

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
por: Goel, Arun Kumar, et al.
Publicado: (2010)

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Tanino, Hirokazu, et al.
Publicado: (2016)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Jung, Yoon Yang, et al.
Publicado: (2016)

The Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy and the Epithelial–Mesenchymal Transition
por: Zapperi, Stefano, et al.
Publicado: (2023)

Postmastectomy radiotherapy reduces locoregional and disease recurrence in patients with stage II–III triple-negative breast cancer treated with neoadjuvant chemotherapy and mastectomy
por: Chen, Xingxing, et al.
Publicado: (2018)

Screening of DNA Damage Repair Genes Involved in the Prognosis of Triple-Negative Breast Cancer Patients Based on Bioinformatics
por: Wang, Nan, et al.
Publicado: (2021)

A gene expression signature in HER2+ breast cancer patients related to neoadjuvant chemotherapy resistance, overall survival, and disease-free survival
por: Barrón-Gallardo, Carlos A., et al.
Publicado: (2022)

Immune Classification and Immune Landscape Analysis of Triple-Negative Breast Cancer
por: Hu, Shaojun, et al.
Publicado: (2021)

Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin
por: Wang, Ruo-Xi, et al.
Publicado: (2016)

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
por: Santonja, Angela, et al.
Publicado: (2018)

Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Nakashoji, Ayako, et al.
Publicado: (2017)

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
por: Lehmann, Brian D., et al.
Publicado: (2016)

Comment on “Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer”
por: Altundag, Kadri
Publicado: (2017)

ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy
por: Jin, Zining, et al.
Publicado: (2015)

Association between the methylation status of PCDH17 and the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer
por: Kong, De-Di, et al.
Publicado: (2020)

The Functional Impact of Alternative Splicing on the Survival Prognosis of Triple-Negative Breast Cancer
por: Wu, Sijia, et al.
Publicado: (2021)

The Role of Mammographic Calcification in the Neoadjuvant Therapy of Breast Cancer Imaging Evaluation
por: Li, Jun-jie, et al.
Publicado: (2014)

Imaging genetic association analysis of triple-negative breast cancer based on the integration of prior sample information
por: Ning, Shipeng, et al.
Publicado: (2023)

Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy
por: Loizides, Sotiris, et al.
Publicado: (2023)

Multiomics technologies for comprehensive tumor microenvironment analysis in triple-negative breast cancer under neoadjuvant chemotherapy
por: Wang, Gang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_17ii7v7t17plkdr8a9msqkc5tf